Journal of Clinical Oncology, Vol 12, 1535-1540, Copyright © 1994 by American Society of Clinical Oncology

ARTICLES

Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study

RP Abratt, WR Bezwoda, G Falkson, L Goedhals, D Hacking and TA Rugg
Department of Oncology, University of Cape Town, South Africa.

PURPOSE: The aim of this study was to evaluate the efficacy and toxicity of gemcitabine at higher doses than had been used previously in patients with non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS: Eighty-four patients (65 men, 19 women; age range, 35 to 75 years; mean age, 59 years) with locally advanced or metastatic pathologically documented NSCLC were enrolled. Patients had bidimensionally measurable disease, as defined by computed tomographic (CT) scan or chest x-ray. A total of 28.6% had previously been surgically treated, while 9.5% had received radiotherapy. Fifty-three patients commenced at a dose of 1,000 mg/m2, and 31 at a dose of 1,250 mg/m2. Patients were to receive two dose escalations of 25%, provided that overall toxicity was no worse than World Health Organization (WHO) grade 1 or WHO grade 0 for platelets. Responding patients were reviewed and validated by a blinded oncology review board (ORB) of experts not involved with the study. Of the original 84 patients enrolled, 76 were assessable. RESULTS: The overall response rate was 20% (95% confidence interval [CI], 11.6% to 30.8%). There were two complete responses (3%) and 13 partial responses (17%). Hematologic toxicity was negligible. WHO grade 3 WBC toxicity occurred in 0.9% of doses and WHO grade 4 in 0.1%. WHO grade 3 and 4 thrombocytopenia occurred in 0.1% and 0.1% of all doses, respectively. Nonhematologic toxicity was minor and easily controlled. Common side effects included peripheral edema, asthenia, and transient malaise. CONCLUSION: The single-agent efficacy of gemcitabine is equivalent to other agents commonly used to treat NSCLC. Gemcitabine has an unusually mild side effect profile for such an active agent. The nausea and vomiting experienced with gemcitabine are mild and generally well controlled with standard antiemetics; 5-HT3 receptor antagonists are typically not required. The use of gemcitabine does not cause significant alopecia, and hematologic toxicity is modest and unlikely to require hospitalization. Gemcitabine may have a role as monotherapy in patients with inoperable NSCLC.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J. A. Treat, R. Gonin, M. A. Socinski, M. J. Edelman, R. B. Catalano, D. M. Marinucci, R. Ansari, H. H. Gillenwater, K. M. Rowland, R. L. Comis, et al. A randomized, phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in patients with advanced or metastatic non-small-cell lung cancer Ann. Onc., October 15, 2009; (2009) mdp352v1. [Abstract] [Full Text] [PDF]

				S. A. Veltkamp, J. H. Beijnen, and J. H.M. Schellens Prolonged Versus Standard Gemcitabine Infusion: Translation of Molecular Pharmacology to New Treatment Strategy Oncologist, March 1, 2008; 13(3): 261 - 276. [Abstract] [Full Text] [PDF]

				X.M. Li and F. Levi Circadian Physiology Is a Toxicity Target of the Anticancer Drug Gemcitabine in Mice J Biol Rhythms, April 1, 2007; 22(2): 159 - 166. [Abstract] [PDF]

				T. Yoshimasu, S. Oura, I. Hirai, T. Tamaki, Y. Kokawa, K. Hata, F. Ohta, R. Nakamura, M. Kawago, H. Tanino, et al. Data acquisition for the histoculture drug response assay in lung cancer J. Thorac. Cardiovasc. Surg., February 1, 2007; 133(2): 303 - 308. [Abstract] [Full Text] [PDF]

				C. Belani, S Dakhil, D. Waterhouse, C. Desch, D. Rooney, R. Clark, M. Monberg, Z Ye, and C. Obasaju Randomized phase II trial of gemcitabine plus weekly versus three-weekly paclitaxel in previously untreated advanced non-small-cell lung cancer Ann. Onc., January 1, 2007; 18(1): 110 - 115. [Abstract] [Full Text] [PDF]

				F. Ohyanagi, F. Taguchi, T. Horai, K. Kasahara, Y. Takeda, K. Shibata, H. Shirosaki, and M. Nishio Phase II Study of Combination Chemotherapy with Gemcitabine and Irinotecan in Patients with Advanced Non-Small-Cell Lung Cancer Previously Treated with Platinum-Containing Chemotherapy Regimens Jpn. J. Clin. Oncol., September 1, 2006; 36(9): 547 - 551. [Abstract] [Full Text] [PDF]

				J.-L. Pujol, J.-L. Breton, R. Gervais, P. Rebattu, A. Depierre, J.-F. Morere, B. Milleron, D. Debieuvre, D. Castera, P.-J. Souquet, et al. Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin Ann. Onc., April 1, 2005; 16(4): 602 - 610. [Abstract] [Full Text] [PDF]

				J. M. Reid, W. Qu, S. L. Safgren, M. M. Ames, M. D. Krailo, N. L. Seibel, J. Kuttesch, and J. Holcenberg Phase I Trial and Pharmacokinetics of Gemcitabine in Children With Advanced Solid Tumors J. Clin. Oncol., June 15, 2004; 22(12): 2445 - 2451. [Abstract] [Full Text] [PDF]

				C. M. Rocha Lima, N. A. Rizvi, C. Zhang, J. E. Herndon 2nd, J. Crawford, R. Govindan, G. W. King, and M. R. Green Randomized phase II trial of gemcitabine plus irinotecan or docetaxel in stage IIIB or stage IV NSCLC Ann. Onc., March 1, 2004; 15(3): 410 - 418. [Abstract] [Full Text] [PDF]

				P. J. Mansky, J. Grem, D. B. Wallerstedt, B. P. Monahan, and M. R. Blackman Mistletoe and Gemcitabine in Patients with Advanced Cancer: A Model for the Phase I Study of Botanicals and Botanical-Drug Interactions in Cancer Therapy Integr Cancer Ther, December 1, 2003; 2(4): 345 - 352. [Abstract] [PDF]

				J. W. G. van Putten, A. Price, A. H. D. van der Leest, A. Gregor, F. A. Little, and H. J. M. Groen A Phase I Study of Gemcitabine with Concurrent Radiotherapy in Stage III, Locally Advanced Non-Small Cell Lung Cancer Clin. Cancer Res., July 1, 2003; 9(7): 2472 - 2477. [Abstract] [Full Text] [PDF]

				W. Scheithauer, B. Schull, H. Ulrich-Pur, K. Schmid, M. Raderer, K. Haider, W. Kwasny, D. Depisch, B. Schneeweiss, F. Lang, et al. Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial Ann. Onc., January 1, 2003; 14(1): 97 - 104. [Abstract] [Full Text] [PDF]

				K. Miura, E. D. Bowman, R. Simon, A. C. Peng, A. I. Robles, R. T. Jones, T. Katagiri, P. He, H. Mizukami, L. Charboneau, et al. Laser Capture Microdissection and Microarray Expression Analysis of Lung Adenocarcinoma Reveals Tobacco Smoking- and Prognosis-related Molecular Profiles Cancer Res., June 1, 2002; 62(11): 3244 - 3250. [Abstract] [Full Text] [PDF]

				V. Gandhi, W. Plunkett, M. Du, M. Ayres, and E. H. Estey Prolonged Infusion of Gemcitabine: Clinical and Pharmacodynamic Studies During a Phase I Trial in Relapsed Acute Myelogenous Leukemia J. Clin. Oncol., February 1, 2002; 20(3): 665 - 673. [Abstract] [Full Text] [PDF]

				C. P. Jung, M. V. Motwani, and G. K. Schwartz Flavopiridol Increases Sensitization to Gemcitabine in Human Gastrointestinal Cancer Cell Lines and Correlates with Down-Regulation of Ribonucleotide Reductase M2 Subunit Clin. Cancer Res., August 1, 2001; 7(8): 2527 - 2536. [Abstract] [Full Text] [PDF]

				T. H. Doyle, F. Mornex, and W. G. McKenna The Clinical Implications of Gemcitabine Radiosensitization Clin. Cancer Res., February 1, 2001; 7(2): 226 - 228. [Full Text]

				S. Okada, H. Ueno, T. Okusaka, M. Ikeda, J. Furuse, and Y. Maru Phase I Trial of Gemcitabine in Patients with Advanced Pancreatic Cancer Jpn. J. Clin. Oncol., January 1, 2001; 31(1): 7 - 12. [Abstract] [Full Text] [PDF]

				S. C. H. Chen, M.-C. Lin, J. W. C. Chang, S.-W. Wang, C.-H. Lee, and T. C. Y. Tsao Phase II Study of Regimen of Gemcitabine and Cisplatin in Advanced Non-small Cell Lung Cancer Jpn. J. Clin. Oncol., November 1, 2000; 30(11): 494 - 498. [Abstract] [Full Text] [PDF]

				K. Kelly, N. Mikhaeel-Kamel, Z. Pan, J. Murphy, S. Prindiville, and P. A. Bunn Jr. A Phase I/II Trial of Paclitaxel, Carboplatin, and Gemcitabine in Untreated Patients with Advanced Non-Small Cell Lung Cancer Clin. Cancer Res., September 1, 2000; 6(9): 3474 - 3479. [Abstract] [Full Text]

				N. Masuda, S. Negoro, S. Kudoh, T. Sugiura, K. Nakagawa, H. Saka, M. Takada, H. Niitani, and M. Fukuoka Phase I and Pharmacologic Study of Docetaxel and Irinotecan in Advanced Non-Small-Cell Lung Cancer J. Clin. Oncol., August 16, 2000; 18(16): 2996 - 3003. [Abstract] [Full Text] [PDF]

				Y.-M. Chen, R.-P. Perng, K.-Y. Yang, T.-W. Liu, C.-M. Tsai, J. Ming-Liu, and J. Whang-Peng A Multicenter Phase II Trial of Vinorelbine Plus Gemcitabine in Previously Untreated Inoperable (Stage IIIB/IV) Non-small Cell Lung Cancer Chest, June 1, 2000; 117(6): 1583 - 1589. [Abstract] [Full Text] [PDF]

				N. Masuda, K. Matsui, N. Yamamoto, T. Nogami, K. Nakagawa, S. Negoro, K. Takeda, N. Takifuji, M. Yamada, S. Kudoh, et al. Phase I Trial of Oral 2'-Deoxy-2'-methylidenecytidine: On a Daily 14-day Schedule Clin. Cancer Res., June 1, 2000; 6(6): 2288 - 2294. [Abstract] [Full Text]

				M. J. Banach and G. A. Williams Purtscher Retinopathy and Necrotizing Vasculitis With Gemcitabine Therapy Arch Ophthalmol, May 1, 2000; 118(5): 726 - 727. [Full Text] [PDF]

				V. Lorusso, F. Carpagnano, G. Frasci, N. Panza, G. Di Rienzo, M. L. Cisternino, G. Napoli, S. Orlando, S. Cinieri, C. Brunetti, et al. Phase I/II Study of Gemcitabine Plus Vinorelbine as First-Line Chemotherapy of Non-Small-Cell Lung Cancer J. Clin. Oncol., January 14, 2000; 18(2): 405 - 405. [Abstract] [Full Text] [PDF]

				A. B. Sandler, J. Nemunaitis, C. Denham, J. von Pawel, Y. Cormier, U. Gatzemeier, K. Mattson, Ch. Manegold, M. C. Palmer, A. Gregor, et al. Phase III Trial of Gemcitabine Plus Cisplatin Versus Cisplatin Alone in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer J. Clin. Oncol., January 5, 2000; 18(1): 122 - 122. [Abstract] [Full Text] [PDF]

				D. Pectasides, A. Aspropotamitis, A. Halikia, A. Visvikis, F. Antoniou, A. Kalantaridou, N. Karvounis, S. Batzios, and A. Athanassiou Combination Chemotherapy With Carboplatin, Docetaxel, and Gemcitabine in Advanced Non-Small-Cell Lung Cancer: A Phase II Study J. Clin. Oncol., December 1, 1999; 17(12): 3816 - 3821. [Abstract] [Full Text] [PDF]

				L. Crino, G. V. Scagliotti, S. Ricci, F. De Marinis, M. Rinaldi, C. Gridelli, A. Ceribelli, R. Bianco, M. Marangolo, F. Di Costanzo, et al. Gemcitabine and Cisplatin Versus Mitomycin, Ifosfamide, and Cisplatin in Advanced Non-Small-Cell Lung Cancer: A Randomized Phase III Study of the Italian Lung Cancer Project J. Clin. Oncol., November 1, 1999; 17(11): 3522 - 3530. [Abstract] [Full Text] [PDF]

				A. Sandler and D. S. Ettinger Gemcitabine: Single-Agent and Combination Therapy in Non-Small Cell Lung Cancer Oncologist, June 1, 1999; 4(3): 241 - 251. [Abstract] [Full Text]

				P. Comella, G. Frasci, N. Panza, L. Manzione, V. Lorusso, G. Di Rienzo, R. Cioffi, G. De Cataldis, L. Maiorino, D. Bilancia, et al. Cisplatin, Gemcitabine, and Vinorelbine Combination Therapy in Advanced Non–Small-Cell Lung Cancer: A Phase II Randomized Study of the Southern Italy Cooperative Oncology Group J. Clin. Oncol., May 1, 1999; 17(5): 1526 - 1526. [Abstract] [Full Text] [PDF]

				V. Georgoulias, C. Kouroussis, N. Androulakis, S. Kakolyris, M.-A. Dimopoulos, E. Papadakis, D. Bouros, F. Apostolopoulou, C. Papadimitriou, A. Agelidou, et al. Front-Line Treatment of Advanced Non–Small-Cell Lung Cancer With Docetaxel and Gemcitabine: A Multicenter Phase II Trial J. Clin. Oncol., March 1, 1999; 17(3): 914 - 914. [Abstract] [Full Text] [PDF]

				R. V. Iaffaioli, A. Tortoriello, G. Facchini, F. Caponigro, M. Gentile, N. Marzano, A. Gravina, P. Dimitri, G. Costagliola, A. Ferraro, et al. Phase I-II Study of Gemcitabine and Carboplatin in Stage IIIB-IV Non–Small-Cell Lung Cancer J. Clin. Oncol., March 1, 1999; 17(3): 921 - 921. [Abstract] [Full Text] [PDF]

				F. Cardenal, M. P. Lopez-Cabrerizo, A. Anton, V. Alberola, B. Massuti, A. Carrato, I. Barneto, M. Lomas, M. Garcia, P. Lianes, et al. Randomized Phase III Study of Gemcitabine-Cisplatin Versus Etoposide-Cisplatin in the Treatment of Locally Advanced or Metastatic Non–Small-Cell Lung Cancer J. Clin. Oncol., January 1, 1999; 17(1): 12 - 12. [Abstract] [Full Text] [PDF]

				C. J.A. van Moorsel, G. J. Peters, and H. M. Pinedo Gemcitabine: Future Prospects of Single-Agent and Combination Studies Oncologist, June 1, 1997; 2(3): 127 - 134. [Abstract] [Full Text] [PDF]

				{blacktriangledown}Gemcitabine for lung cancer DTB, September 1, 1996; 34(9): 71 - 72. [Abstract] [Full Text] [PDF]